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Abstract
Background: Dedifferentiated liposarcoma is an uncommon variant of liposarcoma, with poor prognosis and
higher preponderance to local recurrence. Only nine cases of dedifferentiated liposarcoma of small bowel
mesentery have been reported till now. This is a case of giant dedifferentiated liposarcoma of the small bowel
mesentery, weighing nearly 9 kg (19.8 lbs), with synchronous lesions in the extraperitoneal space, which is the
first such case to be reported.
Case presentation: We report a case of a 62-year-old man, who presented with a huge abdominal mass
occupying nearly the entire abdomen. A contrast enhanced computed tomography of abdomen and pelvis
revealed a large, poorly enhancing, heterogeneous, lobulated mass of size 27 × 16 cm, displacing the bowel loops
peripherally. At laparotomy, a large mass arising from the small bowel mesentery was found. In addition, many
other smaller synchronous lesions were studded in the entire small bowel mesentery and a couple more in the
extraperitoneal space. A palliative excision of the giant mass along with the adjacent small bowel was done. The
other smaller swellings were not causing any mass effect and were left behind as they were numerous, virtually
ruling out any possibility of a curative excision. The histopathological examination suggested the diagnosis of
dedifferentiated liposarcoma. On immunohistochemistry, S-100 was positive in the well-differentiated sarcomatous
areas. The CD 117 and SMA were strongly negative ruling out the possibility of a gastrointestinal stromal tumour.
The CD 34 however was positive in the tumour cells.
Conclusions: Dedifferentiated liposarcoma of the small bowel mesentery is rare. Involvement of nearly whole of
the small bowel mesentery in the disease process virtually rules out the possibility of a curative resection, the
mainstay of management. This report would add to the knowledge of this rare disease and the possible
therapeutic problem that may be encountered in case of multifocal disease.
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Background
Liposarcoma is the most common soft tissue sarcoma in
adults [1]. Evans, in 1979, was the first to identify the
dedifferentiated variant of liposarcoma [2]. Dedifferen-
tiated liposarcomas (DDLPS) have features of well-
differentiated as well as poorly differentiated liposarcoma
along with nonlipomatous sarcoma in the same tumour.
The prognosis of DDLPS variant of liposarcoma is worse
than the well-differentiated ones, but better than the pleo-
morphic type. The retroperitoneum is the most frequent
site of its occurrence [1, 2]. DDLPS affecting the small
bowel mesentery is a rarity [2]. This case of dedifferen-
tiated liposarcoma of small bowel mesentery is being re-
ported for the therapeutic problem posed by the presence
of a large number of nodules in the mesentery as well as a
few in the extraperitoneal space. Multiple DDLPS of the
small bowel mesentery with synchronous lesions in the
extraperitoneal space is the first such case to be reported,
to the best of our knowledge.
Case presentation
A 62-year-old man presented to us with history of a
palpable abdominal mass, vague left side abdominal pain
and loss of appetite for 2 months. The bowel habits were
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normal, and there was no history of weight loss. He was
a known hypertensive on medications. On examination,
the patient was thin built and had a huge abdominal
mass extending from the epigastrium to the hypogas-
trium including both the flanks.
The routine hematogical and biochemical parameters
were within normal limits. The tumour markers includ-
ing CA19-9, carcinoembryonic antigen (CEA) and CA-
125 levels were also within normal limits. Abdominal
sonography revealed a heterogeneous, nodular, soft tis-
sue mass nearly filling the abdominal cavity. Computed
tomography showed a large, poorly enhancing, lobulated
soft tissue mass of size 27 × 16 cm with fluid densities.
The mass was displacing the bowel loops peripherally
(Fig. 1). There was no evidence of calcification or
ascites.
On laparotomy, a huge well-circumscribed lobulated
mass was identified arising from the jejunal mesentery
20 cm away from the ligament of Trietz. Multiple nodu-
lar lesions were found adjacent to the main tumour
mass, largest measuring 3.5 × 2.5 × 3 cm (Fig. 2). There
were two extraperitoneal nodules measuring 2.5 cm ×
2.5 cm in size in maximum dimensions, present one at
the right deep inguinal ring, and the other near the right
iliac vessels. Segmental resection of the small bowel was
done including the tumour mass and the mesenteric
nodules.
Gross examination revealed a large lobulated mass of
size 35 × 25 × 25 cm, weighing 9 kg (19.8 lbs). Cut sec-
tion showed a greyish yellow, soft to firm tumour with
solid components along with myxoid area in less than
50 % area. The attached small bowel with mesentery
measured 40 cm. There were multiple nodules over the
mesentery, largest measuring 3.5 × 2.5 × 3 cm and smal-
lest measuring 0.5 × 0.5 cm.
Histopathological examination showed a partially en-
capsulated tumour composed of spindle cells, arranged
in long and short fascicles and in storiform pattern. The
neoplastic cells were oval to spindloid with round to oval
pleomorphic hyperchromatic nuclei, with prominent nu-
cleoli. Binucleated and multinucleated giant cells were
seen. Round cells with nucleus pushed laterally with vac-
uolated cytoplasm resembling lipoblasts were present
interspersed in between the tumour cells. There was a
zone of transition between the well-differentiated area to
a high-grade sarcomatous area with extensive coagula-
tive necrosis, hyalinisation and myxoid changes. Mono-
nuclear cell infiltration including lymphocytes and
plasma cells were present. Mitotic rate was 8–10/10 per
high power field. A diagnosis of dedifferentiated liposar-
coma was made based on the basis of histological fea-
tures. On immunohistochemistry, S-100 was positive in
the well-differentiated sarcomatous areas. The CD 117
and SMA were strongly negative ruling out the possibil-
ity of a gastrointestinal stromal tumour (GIST). The CD
34 however was positive in the tumour cells. In the first
follow-up after 1 month, the patient had gained weight
and had regained his appetite. He had a general overall
feeling of well-being. There was no significant problem
at 10 months post surgery.
Discussion
According to the WHO, lipomatous tumours are classi-
fied into benign, intermediate and malignant types. The
Fig. 1 CECT abdomen and pelvis, showing a large poorly enhancing heterogeneous mass
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well-differentiated liposarcoma belongs to the intermedi-
ate variety being locally aggressive. The malignant type
includes the dedifferentiated, myxoid, round cell, pleo-
morphic, mixed and liposarcoma not otherwise specified
types. The dedifferentiated variant of liposarcoma is
thrice more common in the retroperitoneum than in the
extremities, where well-differentiated liposarcomas are
more usual [1]. DDLPS primarily arising from the
gastrointestinal tract or its secondary involvement is
very unusual [2, 3]. DDLPS involving small bowel mes-
entery is a rare entity, with nine such cases having been
described in the literature as of now (Table 1).
The early symptoms of this disease are nonspecific;
they present as abdominal lumps when they attain large
sizes and may cause pressure symptoms [2, 3]. X-ray,
ultrasonography, computed tomography and MRI can be
used for radiological assessment of the tumour [4]. Mes-
enteric angiography has been used to ascertain the loca-
tion of the tumour preoperatively [5]. Needle biopsy can
be fallacious due to inadequate sampling, making it diffi-
cult to distinguish from high-grade sarcomas [2, 3].
Thorough sampling from different sites of the tumour is
mandatory as it is as important to identify the nonlipo-
genic component as it to see the well-differentiated areas
to reach at the diagnosis [3]. Hence, post operative histo-
pathology is the only reliable method of stamping the
diagnosis of DDLPS. Histological DDLPS is characterised
by a mixture of atypical lipoma (ALT)/well-differentiated
liposarcoma (WDLPS) and a high-grade nonlipogenic sar-
comatous component, usually with an abrupt transition
between the two components [1–3]. Dedifferentiated areas
exhibit a wide morphological spectrum and often show a
high-grade sarcoma resembling a malignant fibrous histio-
cytoma (MFH) or low-grade spindle cell sarcoma [1–3].
Distinction of different subtypes of liposarcoma on
histopathological examination and immunohistochemis-
try is important because DDLPS is the variant of liposar-
coma having worse prognosis than the well-differentiated
variety. Its clinical course however is less aggressive than
other types of high-grade sarcoma. [1–3]. Due to its prox-
imity to the bowel, it becomes imperative to distinguish
DDLPS from GIST. CD117 (c-kit) and CD34 which are
expressed in GIST are usually negative in DDLPS [2, 3]. In
our case, CD117 and SMA were negative. The CD 34
however was positive in our case. It is worth emphasising
that CD 34 expression is not specific to GIST, and it may
also be positive in tumours like solitary fibrous tumour, in-
flammatory fibrous polyps and dedifferentiated lipo-
sarcoma [6]. MDM2 amplification demonstrated by
florescent in situ hybridisation (FISH) technique, immu-
nohistochemistry, and quantitative PCR help in the diag-
nosis of lipomatous tumours. Hence, it may have a role in
differentiating these tumours from the poorly differenti-
ated sarcomas [4]. p53 has a tumour suppression role.
Fig. 2 a Post operative specimen showing a huge, well-circumscribed lobulated mass with multiple mesenteric nodules. b The well-differentiated
areas showing lipoblasts. c The nonlipomatous areas showing spindle cells, arranged in long and short fascicles and in storiform pattern.
d Tumour cell showing CD 34 positivity
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Mutations of this gene therefore are associated with car-
cinogenesis and tumours with poor prognosis. Karaman et
al. found p53 gene mutation in nonlipomatous component
of dedifferentiated sarcomas and not in the well-
differentiated areas [7].
Complete surgical resection is the only effective treat-
ment option available [4]. Efforts to remove the tumour
completely often require the removal of an organ or part
of an organ to which it is adherent [3, 4]. Even palliative
resection is sometimes helpful to treat troublesome
symptoms of recurrence [5, 8]. The negative margins of
surgical resection are associated with disease-free sur-
vival and overall survival [4]. Although the evidence sup-
porting the use of chemotherapy and radiotherapy is
limited [3, 4], they may be of benefit in poorly differenti-
ated sarcomas more than 10 cm in size or if there is re-
sidual disease after a palliative surgery [9]. Ifosfamide in
high doses has been tried in recurrent DDLPS, after re-
currence [4]. However, approximately 40 % of DDLPS
will have local recurrence, 17 % will metastasize and
28 % will have tumour-related mortality [1].
Conclusions
Dedifferentiated liposarcoma is a variant of liposarcoma
having worse prognosis and higher risk of local recurrence
than the well-differentiated variety. Hence, accurate histo-
pathological diagnosis is essential for prognostication and
closer follow-up. Complete surgical excision with negative
margin is associated with overall survival and disease-free
survival. However, DDLPS at multiple locations in the
mesentery is a possibility which may exclude the chance
of curative resection. Palliative resection upfront, of large
offending masses, or upon recurrence will have the benefit
by relieving pressure symptoms due to the tumour. The
scope of adjuvant chemotherapy and radiotherapy is
limited to recurrent, residual or poorly differentiated
liposarcomas.
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